VRTX

Vertex Pharmaceuticals Incorporated

467.18 USD
-6.49 (-1.37%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Vertex Pharmaceuticals Incorporated stock is up 4.78% since 30 days ago. The next earnings date is Jul 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 32 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 1 PUT, 9 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
14 Jun 18:07 18 Oct, 2024 450.00 PUT 300 37
17 Jun 13:30 18 Oct, 2024 490.00 CALL 25 23
17 Jun 15:30 17 Jan, 2025 530.00 CALL 15 10
17 Jun 16:53 18 Oct, 2024 430.00 CALL 9 37
17 Jun 19:03 20 Sep, 2024 460.00 CALL 132 243
17 Jun 19:03 21 Jun, 2024 440.00 CALL 132 549
18 Jun 16:42 17 Jan, 2025 500.00 CALL 10 307
18 Jun 16:42 17 Jan, 2025 500.00 CALL 10 307
18 Jun 18:03 21 Jun, 2024 440.00 CALL 20 483
18 Jun 18:27 20 Sep, 2024 430.00 CALL 5 92

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.

  • Argus Research
    Mon Jun 17, 13:04
    buy
    confirm
  • RBC Capital
    Tue Jun 11, 07:34
    hold
    confirm
  • RBC Capital
    Tue Jun 4, 09:48
    hold
    confirm
  • BMO Capital
    Fri May 31, 09:41
    buy
    confirm